Pentixapharm Narrows 2026 Net Loss Forecast to About EUR 13 Million From EUR 21.6 Million

• Pentixapharm raised its 2026 earnings guidance, forecasting a net loss of approximately EUR 13 million versus approximately EUR 21.6 million previously.
• Cash expenses fall by approximately EUR 3 million from PANDA study deferrals, with approximately EUR 2 million from other savings and deferrals.
• A noncash benefit of approximately EUR 3.7 million primarily reflects the elimination of scheduled amortization of intangible assets.
• PANDA Phase 3 first-patient enrollment shifts to first-quarter 2027 from second-half 2026, with no material impact expected on the remaining study timeline.
• Available financial resources remain sufficient to fund operations into 2028 despite the revised study schedule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2418374_en) on October 19, 2026, and is solely responsible for the information contained therein.